Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
JANX
SELLJanux Therapeutics, Inc. · Healthcare · United States · $935M · Avg Vol: $20M/d
COMPANY DESCRIPTION
Janux Therapeutics, Inc. is a clinical-stage biotechnology company developing novel T-cell engager immunotherapies for cancer, utilizing its proprietary Tumour Activated T Cell Engager (TRACTr) platform. The company's innovative TRACTr platform is designed to improve the therapeutic index of T-cell engagers by reducing off-tumor toxicity. It is a niche biopharmaceutical company specializing in next-generation T-cell engager technology for oncology, aiming for safer and more effective cancer treatments.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 8.6M | 8.1M | 10.6M | 10.0M | 5.1% | 13.7M | 31.6M | 7.0M | -16.6% |
| EPS | -1.39 | -1.52 | -1.32 | -1.28 | -1.83 | — | -1.82 | -1.76 | -2.70 | — |
| Shares | — | 41.6M | 46.3M | 59.1M | 60.4M | +45.1% | 61.0M | — | — | — |
| Debt | — | 25.3M | 24.5M | 23.0M | 22.1M | -4.4% | 21.6M | — | — | — |
| Equity | — | 320.7M | 344.3M | 1.0B | 956.8M | 44.0% | — | — | — | — |
| Op CF | — | -42.9M | -50.6M | -43.8M | -82.2M | — | -77.5M | — | — | — |
| Inv CF | — | 58.3M | -41.2M | -258.0M | -301.0M | — | — | — | — | — |
| Fin CF | — | 0.5M | 59.5M | 713.2M | 4.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of JANX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| JANX | Janux Therapeutics, Inc.(you) | $935M | 24 | SELL |
| AVTX | Avalo Therapeutics, Inc. | $976M | 25 | SELL |
| ANL | Adlai Nortye Ltd. | $805M | 24 | SELL |
| PHAT | Phathom Pharmaceuticals, Inc. | $912M | 21 | SELL |
| GERN | Geron Corporation | $911M | 27 | SELL |
| SLDB | Solid Biosciences Inc. | $771M | 25 | SELL |
| KURA | Kura Oncology, Inc. | $922M | 19 | STRONG SELL |
| REPL | Replimune Group, Inc. | $814M | 26 | SELL |
| AURA | Aura Biosciences, Inc. | $729M | 24 | SELL |
| DRUG.CN | Bright Minds Biosciences Inc. | $727M | 24 | SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.6%